Migraine in Full: What Happens in the Brain and How Attacks Are Managed

Mistaking migraine for merely a severe headache is the most common error; the shared verdict of eleven video narratives is that it is a complex disease of the nervous system. It affects more than 1 billion people worldwide, strikes women about three times as often as men, and lifetime rates converge around 33 percent in women and 13-14 percent in men. The "just a headache" narrative silences patients, yet the disease ranks among the leading causes of disability in young adults; this guide merges eleven narratives with current medical sources into one frame.

The brain itself has no pain receptors; in a headache, what hurts is not the brain but the meninges, vessels, and sinuses around it. Signals from these structures travel through the trigeminal nerve, and the brain interprets them as pain. Migraine pain is therefore not the brain aching but the alarm of the system surrounding it.

During an attack, trigeminal fibers release a signaling molecule called CGRP, which dilates the smooth muscle of vessels and sensitizes neighboring pain fibers. The result is neurogenic inflammation with throbbing pain. Most modern preventive treatments target exactly this pathway, which is why CGRP is the key concept of this guide.

Aura is the product of a slow electrical wave crossing the cortex: a brief excitation followed by a phase of suppression. Known as Leao's spreading depression, this wave produces temporary symptoms as it passes through visual, sensory, and speech areas. The process is benign but frightening for those who experience it.

Migraine runs in families; the risk rises markedly when close relatives are affected, and genes set the threshold together with hormones. Falling estrogen is the strongest hormonal trigger; attacks linked to the menstrual cycle can resist treatment, and estrogen-containing contraceptives worsen the picture in some women. The fluctuating pre-menopause years can also raise attack frequency.

An attack often starts hours, sometimes days, before the pain: yawning, food cravings, neck stiffness, mood shifts, and frequent urination mark this prodrome phase. The brain has been shown to be unusually active in this phase. Those who learn to read these signals gain a chance to prepare for the attack.

The most common auras are visual: flashes of light, shimmering zigzag lines, and temporary blind spots, usually lasting 5 to 60 minutes. Numbness, tingling, and speech difficulty are rarer and can mimic stroke. The difference is the slow spread of symptoms; anyone experiencing aura for the first time should be evaluated without delay.

In the headache phase, pain is typically one-sided and throbbing, worsens with movement, and can last from 4 hours up to 72. Nausea, vomiting, sensitivity to light, sound, and smell, plus the urge to retreat into a dark quiet room, complete the picture. Clinicians use the POUND rule: pulsating pain, one-sidedness, duration up to 72 hours, nausea, and disabling intensity.

The picture does not end when pain fades; in the postdrome phase, lasting up to a day, fatigue, grogginess, poor concentration, and neck pain appear. In this so-called migraine hangover, brain fog makes decisions hard. A minority experiences the opposite instead: relief and euphoria.

Telling migraine apart from other primary headaches sets the treatment course: tension-type headache is a bilateral pressure, as if a band were wrapped around the head; cluster headache is a searing pain behind one eye with tearing and a runny nose, lasting 15-180 minutes and arriving in bouts. The migraine triad is throbbing, nausea, and light-sound sensitivity.

Hunting for a single trigger misleads; disrupted sleep, skipped meals, stress and the let-down after stress, alcohol, excess caffeine, bright lights, and sharp smells pile up. The threshold model explains it: the attack does not start until the glass is full, and the last drop merely makes it overflow. A personal attack diary shows which ingredients fill the glass.

Migraine is a clinical diagnosis; no blood test or scan can confirm or exclude it, and the diagnosis rests on the story the patient tells. The criteria are crisp: at least two of one-sidedness, throbbing, moderate-to-severe intensity, and worsening with movement, plus at least one of nausea-vomiting or light-sound sensitivity. Unusual neurological signs, new pain after age 50, thunderclap-like sudden severe pain, or a changed pattern require brain imaging and urgent evaluation.

In acute treatment, paracetamol and anti-inflammatory painkillers are the first step for mild and moderate attacks, with an anti-nausea agent added when needed. Triptans stop severe attacks effectively. The shared rule is to take medication early in the attack, before pain fully settles.

Preventive treatment enters the agenda at four or more migraine days a month; classic options come from blood pressure, antidepressant, and anti-seizure drug groups. Anti-CGRP monoclonal antibodies are the targeted new generation. Prevention does not abolish attacks; it lowers their frequency and severity and reduces acute drug need.

2026 data is lively on the CGRP front: atogepant gained European approval for both preventive and acute use, and a fixed-dose rimegepant-atogepant combination entered the agenda as the first dual gepant. In a phase 3b trial, atogepant was better tolerated than the classic preventive topiramate, with low discontinuation rates. Unanswered questions in the field are closing fast.

Fifteen or more headache days a month, migraine features on at least 8 of them, for longer than three months: this is chronic migraine and deserves separate attention. Frequent painkiller use makes the disease chronic; the practical limit is keeping painkillers under 10 days a month. A daily headache diary reveals use honestly and makes tuning the plan possible.

Daily routine is the ground therapy: regular sleep, an active life, three balanced meals with enough water, keeping an attack diary, and stress management together raise the attack threshold. Deliberately making time for enjoyable activities is part of the prescription too. None of these works miracles alone, but together they firm the ground.

The vitamin B2 story rests on mitochondria: riboflavin plays a role in cellular energy production, and deficiency raises nervous system excitability. Studies show 400 mg of daily riboflavin reducing attack frequency over three months, with a calm side-effect profile. But the evidence level is limited; the landmark trial had only 55 patients, and not every trial returned positive.

The picture is similar for other supplements: magnesium, omega-3 fatty acids, coenzyme Q10, and melatonin have preliminary data, but none reaches firm evidence. The creatine and omega-3 pilot studies in popular narratives belong to a traumatic brain injury context and cannot be carried over to migraine in general. Liver warnings and product quality issues apply to herbal products; supplement choices must be individualized with a physician.

Caffeine is two-faced: it can relieve some attacks, yet regular heavy use and withdrawal produce headaches of their own. Beyond a few cups a week, withdrawal attacks multiply and the picture turns into a vicious circle. The safest strategy is to ration caffeine by calendar and avoid creating withdrawal days.

Sensory and behavioral tools soften attack severity: dim and red-light environments for photophobia, sleep order, relaxation exercises, and biofeedback; individual responses to peppermint oil and acupuncture vary. Regular aerobic exercise has the firmer preventive evidence. These do not stop an attack alone but cut drug need.

In chronic migraine, botulinum toxin is an approved preventive; it works by cutting signal transmission at the nerve-muscle junction through SNAP-25. External nerve stimulation devices are growing as drug-free options. Both are applied with specialist selection, in the right patient, under regular follow-up.

Migraine keeps more common company than it should: depression, panic disorder, sleep disorders, and stroke risk are elevated, and repeated attacks have been shown to leave marks on the brain. Pressure felt around the eyes, jaw, and sinuses is usually not sinusitis but trigeminal migraine pain. Companion diseases must stay inside the treatment plan.

Migraine is chronic but manageable; knowledge of the mechanism, a trigger diary, a stepped drug plan, and an orderly life together make attacks predictable. The personal plan is built with a neurologist, tuned with diary data, and the preventive step is not delayed when frequency rises. This guide promises not a miracle but a sense of control.